

## Novel Druggable Targets and Drug Delivery Systems in Ophthalmology

**Santen**, a Japanese pharmaceutical company leading in transformative solutions in both common and rare ophthalmological conditions, is seeking **new druggable targets and ocular drug delivery systems**, including both the front and the back of the eye.



### Novel Druggable Targets:

- Diseases of interest include **presbyopia, myopia, Fuchs dystrophy**, new targets in **glaucoma** (not just for intraocular pressure lowering), **retinitis pigmentosa, dry eye disease, dry age-related macular degeneration (AMD), geographic atrophy and seasonal allergic conjunctivitis**
- Open to different modalities including **small molecules, biologics, gene therapy, cell therapy and drug repurposing**
- **Patient biomarkers** related to the above mentioned diseases

### Drug Delivery Systems:

- **Non-invasive ocular drug delivery systems** (e.g., cul-de-sac insert, drug delivery system for ocular surface). Requirements include sustained release (several days to weeks), easy administration, no irritation or discomfort, and a concrete development plan until clinical proof-of-concept
- **Injectable drug delivery system for the periocular route**. Requirements include potential 1-6 months release, thinner than 25G needle, and tolerable by the patient
- Open to all types of drug delivery vehicles including **nanoparticles, microneedles, liposomes, nanowafers**, etc

### Out of Scope:

- Therapeutic approaches to treat cataract, uveitis, wet AMD and ocular cancer
- Contact lens and punctal plug drug delivery systems

### Developmental Stages of Interest:

- Opportunities at basic research phase to late stage clinical trial are within scope, provided there is target validation
- Opportunities with *in vitro* proof-of-concept or *in vivo* pharmacokinetic and toxicity validation are of interest

### Submission Information and Opportunity for Collaboration:

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Santen is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations. Santen is looking to establish long-standing partnerships in the field of ophthalmology.

### Opportunities sought

- 💡 Technologies
- 🎓 Academics and expertise
- 🏆 Centres of excellence
- 🧪 Research projects
- 🏢 Spinout companies

### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **23rd January 2023 - 11:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

